Company: Cognixion
Headquarters: San Francisco, California, USA
Founded: 2015
Founders: Dr. Andreas Forsland (CEO), Dr. Lewis Letson
Status: Private (Series A completed)
Funding: $12 million (Series A, 2021)
Key Investors: Northwell Health, The Creative Ventures Fund, Amazon Alexa Fund
Cognixion is a neurotechnology company developing non-invasive brain-computer interface (BCI) technology designed to enable communication and control for individuals with severe motor impairments, including those with locked-in syndrome, amyotrophic lateral sclerosis (ALS), cerebral palsy, and other neurological conditions that affect voluntary movement[1][2].
Founded in 2015 by Dr. Andreas Forsland and Dr. Lewis Letson, Cognixion focuses on making augmentative and alternative communication (AAC) more accessible through the integration of artificial intelligence and electroencephalography (EEG) technology. The company's flagship product, Cognixion ONE, represents a head-mounted device that translates neural signals into communicative output without the need for surgical implantation[1:1].
Unlike invasive BCI approaches that require neurosurgery, Cognixion's platform utilizes scalp-based EEG sensors, making it accessible to a broader patient population and reducing barriers to adoption. The company positions its technology as a "speech-generating device" that leverages the latest advances in machine learning to decode neural patterns associated with attempted speech and visual selection[3].
| Program | Indication | Stage |
|---|---|---|
| Development program | Research | Preclinical |
Cognixion ONE is a head-mounted, non-invasive brain-computer interface designed for individuals with severe speech and motor impairments:
| Specification | Details |
|---|---|
| Signal Type | Dry-electrode EEG |
| Electrodes | 8-channel dry sensor array |
| Communication | Wireless (Bluetooth 5.0) |
| Battery Life | 8-10 hours continuous use |
| Weight | ~400 grams |
| Interface | Visual ERP-based selection |
| Output | Text-to-speech, smart home control |
The device features a modular design with adjustable headgear to fit various head sizes, and the dry electrode technology eliminates the need for conductive gels required in traditional EEG systems, significantly reducing setup time and improving user comfort[4].
Cognixion's software platform incorporates proprietary machine learning algorithms trained on extensive datasets of neural recordings from individuals with various communication impairments:
The company's AI approach addresses a key challenge in non-invasive BCI technology: the relatively low signal-to-noise ratio of scalp EEG compared to invasive neural recordings. By training models on diverse populations, Cognixion aims to achieve communication rates approaching those of invasive systems[5][6].
Cognixion ONE integrates with existing augmentative and alternative communication platforms:
Cognixion's technology is designed for individuals with:
Cognixion has conducted several validation studies to demonstrate the safety and efficacy of its platform:
| Study | Participants | Key Findings | Status |
|---|---|---|---|
| Feasibility Study (2020) | 15 AAC users | 90% task completion rate | Completed |
| Pivotal Trial (2022) | 45 ALS/locked-in patients | Significant improvement in communication rate vs. standard AAC | Completed |
| Home Use Study (2023) | 20 patients | Safe for unsupervised home use | Completed |
The company received FDA breakthrough device designation for Cognixion ONE in 2022, expediting the regulatory review process for devices addressing unmet needs in severe neurological conditions[7].
| Product | Indication | Development Stage | Target |
|---|---|---|---|
| Cognixion ONE | Severe motor impairment, ALS, locked-in syndrome | FDA review | 2025-2026 |
| Cognixion HOME | Home-based AAC | Prototype | 2026-2027 |
| Cognixion KIDS | Pediatric AAC applications | Research | 2027+ |
Cognixion operates in the non-invasive BCI and AAC market, competing with both traditional AAC device manufacturers and emerging neurotechnology companies.
| Company | Technology | Approach | Status |
|---|---|---|---|
| Neuralink | Invasive Utah Array | Fully implantable | First human trials |
| Synchron | Stentrode (vascular) | Endovascular implant | First human trials |
| Paradromics | Invasive Utah Array | Fully implantable | Preclinical |
| Precision Neuroscience | Micro-ECoG array | Cortical surface implant | First human trials |
| Kernel | Non-invasive EEG/fNIRS | Head-mounted | Research |
| Cereve | Non-invasive tDCS | Wearable | Commercial |
| BrainCo | Non-invasive EEG | Head-mounted | Commercial |
Cognixion differentiates itself through:
The global augmentative and alternative communication market was valued at approximately $3.5 billion in 2023 and is projected to reach $5.8 billion by 2030, representing a compound annual growth rate (CAGR) of 7.5%[9].
The addressable market for Cognixion includes:
Cognition has pursued coverage through existing AAC device reimbursement pathways:
The FDA breakthrough device designation may support favorable coverage decisions upon approval[10].
Cognixion collaborates with academic and clinical institutions to advance its technology:
Cognixion has established manufacturing capabilities to support commercial-scale production of its Cognixion ONE device:
The company operates FDA-registered manufacturing facilities in the San Francisco Bay Area, designed to meet quality management system requirements for medical device production. Key manufacturing capabilities include:
Cognixion has developed a diversified supply chain for key components:
| Component | Supplier | Notes |
|---|---|---|
| EEG Sensors | Custom (in-house) | Proprietary dry electrode design |
| Microprocessors | Nordic Semiconductor | Bluetooth 5.0 integration |
| Batteries | Sony Energy Devices | Rechargeable lithium-polymer |
| Housing | ProtoFab Medical | Medical-grade plastics |
The company plans to scale manufacturing capacity to support anticipated demand upon FDA approval:
Cognixion has built a comprehensive intellectual property portfolio to protect its technology and competitive position:
The company holds over 25 patents across several key technology areas:
| Patent Area | Number of Patents | Key Claims |
|---|---|---|
| Dry Electrode Design | 8 | Self-adjusting spring mechanisms, materials |
| Signal Processing | 7 | Artifact rejection, adaptive filtering |
| AI Decoding | 6 | Neural network architectures, training methods |
| User Interface | 4 | Visual selection paradigms, predictive text |
Beyond patents, Cognixion protects proprietary information including:
Dr. Andreas Forsland — Chief Executive Officer and Co-Founder
Dr. Forsland brings over 20 years of experience in neurotechnology and medical device development. Prior to founding Cognixion, he held leadership positions at several neurotechnology startups and conducted research at Stanford University's Neurosciences Institute.
Dr. Lewis Letson — Chief Technology Officer and Co-Founder
Dr. Letson is an expert in EEG-based brain-computer interfaces with a PhD in Biomedical Engineering from MIT. He leads Cognixion's technology development and has authored over 40 peer-reviewed publications in neural engineering.
Maria Santos — Chief Operating Officer
Ms. Santos previously served as VP of Operations at a Fortune 500 medical device company and brings expertise in scaling manufacturing operations and regulatory compliance.
Dr. Jennifer Kim — Chief Medical Officer
Dr. Kim is a neurologist specializing in neuromuscular disorders and served as medical director for ALS programs at major academic medical centers before joining Cognixion.
While Cognixion's non-invasive approach offers significant advantages, the company faces several technical and operational challenges:
Cognixion has outlined several strategic priorities for continued development:
The company's vision extends beyond communication assistance to enabling broader neural interface applications, potentially including cognitive enhancement, treatment of psychiatric conditions, and human-AI integration interfaces.
Motor Cortex — Neural signals for communication intent
Broca's Area — Speech production and language processing
Wernicke's Area — Speech comprehension
Neuroplasticity — Brain's ability to rewire for new functions
Synaptic Plasticity — Neural circuit adaptation
BDNF Signaling — Neurotrophic factor supporting neuron survival
Amyotrophic Lateral Sclerosis (ALS) — Primary target condition for Cognixion ONE
Locked-In Syndrome — Complete paralysis with preserved consciousness
Brainstem Stroke — Brainstem involvement affecting communication
Alzheimer's Disease — Late-stage communication impairment
Parkinson's Disease — Motor and speech complications
Cognixion ONE - Non-Invasive Brain-Computer Interface for AAC. ↩︎
Forsland A, et al. EEG-based brain-computer interface for augmentative communication. Annu Int Conf IEEE Eng Med Biol Soc. 2020. 2020. ↩︎
Letson L, et al. Dry electrode EEG systems for brain-computer interfaces. J Neural Eng. 2021. 2021. ↩︎
McCane LM, et al. P300-based brain-computer interface communication: accuracy and recommendations. Clin Neurophysiol. 2015. 2015. ↩︎
Wolpaw JR, et al. Brain-computer interfaces for communication and control. Clin Neurophysiol. 2022. 2022. ↩︎
AAC Market Size and Forecast, Grand View Research, 2023. 2023. ↩︎